Particle.news
Download on the App Store

Neogen Stock Soars on Q2 Beat, Higher 2026 Outlook

Management frames the performance as early progress in a strategic turnaround supported by regulatory-driven demand for food-safety testing.

Overview

  • Neogen posted adjusted EPS of $0.10 and revenue of about $224.7 million, beating consensus estimates.
  • The company raised fiscal 2026 sales guidance to $845–$855 million and now targets about $175 million in Adjusted EBITDA.
  • Shares rose roughly 28% to 34% intraday Thursday following the report and outlook upgrade.
  • The quarterly net loss narrowed to $15.9 million from $456.3 million in the prior-year period, with core revenue growth of 2.9%.
  • CEO Mike Nassif said the first phase of a strategic transformation is underway as the company benefits from heightened food-contamination concerns and regulatory changes.